WARMINSTER, Pa. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 6, 2019 ....

WARMINSTER, Pa. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation  (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor....

WARMINSTER, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019 : Cantor...

WARMINSTER, Pa. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng , M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17,...

WARMINSTER, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019...

- Appointed William Collier , with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor in subjects with chronic hepatitis B - Initiated dosing in healthy subject portion of...

WARMINSTER, Pa. , July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Monday, August 5,...

Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa. , July 15, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an...

 - Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics  - Runway extended with non-dilutive capital WARMINSTER, Pa. , July 02, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B...

- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa. , June 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...